Human pac1 antibodies
AssigneeAmgen Inc.
InventorsCen XU, Agnes Eva HAMBURGER
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
Claims23
A method for inhibiting vasodilation in a patient in need thereof comprising administering to the patient an effective amount of an isolated monoclonal antibody that specifically binds to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) with an equilibrium binding affinity (KD) of ≦1×10−9M, wherein the monoclonal antibody comprises a human IgG1 heavy chain having a N297G mutation according to EU numbering.
A method for treating a headache condition in a patient in need thereof comprising administering to the patient an effective amount of an isolated monoclonal antibody that specifically binds to human PAC1 with a KD of ≦1×10−9 M, wherein the monoclonal antibody comprises a human IgG1 heavy chain having a N297G mutation according to EU numbering.
Dependencies are inferred from the claim text.